Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

prothena corp. plc - PRTA

PRTA

Close Chg Chg %
14.40 0.13 0.90%

Open Market

14.53

+0.13 (0.90%)

Volume: 125.75K

Last Updated:

Nov 21, 2024, 2:35 PM EDT

Trade Now

Company Overview: prothena corp. plc - PRTA

PRTA Key Data

Open

$14.51

 Day Range

14.20 - 14.69

52 Week Range

13.22 - 41.55

 Market Cap

$774.85M

Shares Outstanding

53.81M

 Public Float

44.79M

Beta

0.16

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$2.46

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

495.07K

  

PRTA Performance

1 Week
 
 2.78%
 
1 Month
 
 -5.88%
 
3 Months
 
 -33.67%
 
1 Year
 
 -56.61%
 
5 Years
 
 34.39%
 

PRTA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 8
Full Ratings ➔

About prothena corp. plc - PRTA

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

PRTA At a Glance

Prothena Corp. Plc
77 Sir John Rogersons Quay
Dublin, Dublin 2
Phone 353-1-236-2500 Revenue 91.37M
Industry Biotechnology Net Income -147,028,000.00
Sector Health Technology 2023 Sales Growth 69.502%
Fiscal Year-end 12 / 2024 Employees 173
View SEC Filings

PRTA Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 21.165
Price to Book Ratio 3.475
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -7.258
Enterprise Value to Sales 14.507
Total Debt to Enterprise Value 0.009

PRTA Efficiency

Revenue/Employee 528,150.289
Income Per Employee -849,872.832
Receivables Turnover 17.711
Total Asset Turnover 0.126

PRTA Liquidity

Current Ratio 11.237
Quick Ratio 11.237
Cash Ratio 10.901

PRTA Profitability

Gross Margin 90.793
Operating Margin -209.08
Pretax Margin -175.638
Net Margin -160.915
Return on Assets -20.218
Return on Equity -24.848
Return on Total Capital -25.65
Return on Invested Capital -24.625

PRTA Capital Structure

Total Debt to Total Equity 2.108
Total Debt to Total Capital 2.065
Total Debt to Total Assets 1.699
Long-Term Debt to Equity 1.91
Long-Term Debt to Total Capital 1.87
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Prothena Corp. Plc - PRTA

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
853.00K 200.58M 53.91M 91.37M
Sales Growth
+4.79% +23,414.30% -73.13% +69.50%
Cost of Goods Sold (COGS) incl D&A
- - 6.74M 8.41M
-
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
6.98M 6.80M 6.74M 8.41M
Depreciation
6.98M 6.80M 6.74M 8.41M
Amortization of Intangibles
- - - -
-
COGS Growth
- - - +24.79%
-
Gross Income
- - 47.16M 82.96M
-
Gross Income Growth
- - - +75.89%
-
Gross Profit Margin
- - +87.49% +90.79%
-
2020 2021 2022 2023 5-year trend
SG&A Expense
106.61M 121.80M 178.72M 273.99M
Research & Development
74.88M 82.28M 135.56M 220.57M
Other SG&A
31.73M 39.52M 43.16M 53.42M
SGA Growth
+33.68% +14.25% +46.73% +53.31%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(112.73M) 71.97M (131.56M) (191.04M)
Non Operating Income/Expense
1.31M (54.00K) 5.95M 30.56M
Non-Operating Interest Income
1.37M 42.00K 6.35M 31.01M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(111.43M) 71.92M (125.61M) (160.48M)
Pretax Income Growth
-44.15% +164.55% -274.64% -27.77%
Pretax Margin
-13,062.95% +35.86% -233.01% -175.64%
Income Tax
(283.00K) 4.95M (8.66M) (13.45M)
Income Tax - Current - Domestic
- - - 2.24M
-
Income Tax - Current - Foreign
- 1.41M 372.00K 2.48M
Income Tax - Deferred - Domestic
- - - (15.69M)
-
Income Tax - Deferred - Foreign
- (1.69M) 4.57M (11.13M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(111.14M) 66.98M (116.95M) (147.03M)
Minority Interest Expense
- - - -
-
Net Income
(111.14M) 66.98M (116.95M) (147.03M)
Net Income Growth
-43.08% +160.26% -274.62% -25.72%
Net Margin Growth
-13,029.78% +33.39% -216.95% -160.91%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(111.14M) 66.98M (116.95M) (147.03M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(111.14M) 66.98M (116.95M) (147.03M)
EPS (Basic)
-2.7845 1.5143 -2.4689 -2.7629
EPS (Basic) Growth
-42.96% +154.38% -263.04% -11.91%
Basic Shares Outstanding
39.91M 44.23M 47.37M 53.22M
EPS (Diluted)
-2.7845 1.382 -2.4689 -2.7629
EPS (Diluted) Growth
-42.96% +149.63% -278.65% -11.91%
Diluted Shares Outstanding
39.91M 48.46M 47.37M 53.22M
EBITDA
(105.76M) 78.78M (124.82M) (182.62M)
EBITDA Growth
-33.97% +174.49% -258.44% -46.31%
EBITDA Margin
-12,398.24% +39.28% -231.55% -199.87%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 61.143
Number of Ratings 8 Current Quarters Estimate -1.004
FY Report Date 12 / 2024 Current Year's Estimate -2.193
Last Quarter’s Earnings -1.10 Median PE on CY Estimate N/A
Year Ago Earnings -2.76 Next Fiscal Year Estimate -3.973
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 8 2 8 8
Mean Estimate -1.00 -1.28 -2.19 -3.97
High Estimates -0.58 -1.22 -1.77 -0.38
Low Estimate -1.22 -1.34 -2.41 -5.62
Coefficient of Variance -18.33 -6.63 -8.41 -46.07

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 6 6 6
OVERWEIGHT 0 0 0
HOLD 2 2 2
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Prothena Corp. Plc - PRTA

Date Name Shares Transaction Value
Oct 4, 2024 Chad J. Swanson Chief Development Officer 40,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2024 David Ford Chief People Officer 85,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 1, 2024 Gene G. Kinney President and CEO 307,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 1, 2024 Carol D. Karp Chief Regulatory Officer 85,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 1, 2024 Hideki Garren Chief Medical Officer 85,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 1, 2024 Tran B. Nguyen Chief Strategy Officer and CFO 85,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 1, 2024 Karin L. Walker Chief Accounting Officer 54,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 1, 2024 Brandon S. Smith Chief Operating Officer 85,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 1, 2024 Wagner M. Zago Chief Scientific Officer 85,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 1, 2024 Michael J. Malecek Chief Legal Officer 85,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 1, 2023 Karin L. Walker Chief Accounting Officer N/A Open market or private sale of non-derivative or derivative security Non-derivative transaction at $34 per share 0.00
Dec 1, 2023 Karin L. Walker Chief Accounting Officer 25,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Prothena Corp. Plc in the News